Replies to post #193550 on Biotech Values

[DewDiligence]

ABT addendum re ‘TGDT’: #msg-115616486.

[DewDiligence]

ABT -7.3%, which is unheard of. Why? Because ABT has large and profitable businesses selling infant formula and branded-generic drugs in China and other emerging markets.

[DewDiligence]

ABT's 3Q15 sales jump 11% in constant currency:

http://finance.yahoo.com/news/abbott-reports-third-quarter-2015-114500954.html

CEO Miles White said, “The slowdown in China does not apply to drugs.”

3Q15 results were adversely affected by the strong US Dollar, but YoY sales growth in constant currency was a robust 11% (excluding the MYL divestiture), the same growth rate as in 2Q15 (#msg-115595440).

ABT tightened 2015 guidance for non-GAAP EPS to $2.14-2.16 (from old range of $2.10-2.10).